Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: A thai multicenter study

Angiology

Volumn 63, Issue 7, 2012, Pages 528-534

  Khovidhunkit, Weerapan ^a   Silaruks, Songkwan ^b   Chaithiraphan, Vithaya ^c   Ongphiphadhanakul, Boonsong ^d   Sritara, Piyamitr ^d   Nimitphong, Hataikarn ^d   Benjanuwattra, Thanawat ^e   Ambegaonkar, Baishali M ^f  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cardiovascular disease; dyslipidemia; goal attainment; prevalence; treatment

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; PREVALENCE; SCORING SYSTEM; THAILAND; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANIMALS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FIBRIC ACIDS; FOLLOW-UP STUDIES; HOSPITALS, TEACHING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; RETROSPECTIVE STUDIES; THAILAND; TRIGLYCERIDES;

EID: 84866403248     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711432451     Document Type: Article

References (29)

1. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 ; 74 (1). 1-12
2. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007 ; 115 (4). 450-458
3. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996 ; 124 (suppl). S11 - S20
4. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 ; 376 (9753). 1670-1681
5. Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010 ; 376 (9738). 333-339
6. Zhang L, Qiao Q, Tuomilehto J, et al. DECODE/DECODA Study Group Distinct ethnic differences in lipid profiles across glucose categories. J Clin Endocrinol Metab. 2010 ; 95 (4). 1793-1801
7. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007 ; 99 (3). 410-414
8. Menotti A, Lanti M, Kromhout D, et al. Homogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries Study. Eur J Cardiovasc Prev Rehabil. 2008 ; 15 (6). 719-725
9. Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003 ; 32 (4). 563-572
10. Khoo KL, Tan H, Liew YM, Deslypere JP, Janus E. Lipids and coronary heart disease in Asia. Atherosclerosis. 2003 ; 169 (1). 1-10
11. France MW, Kwok S, McElduff P, Seneviratne CJ. Ethnic trends in lipid tests in general practice. QJM. 2003 ; 96 (12). 919-923
12. Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord. 2009 ; 7 (6). 497-514
13. Okamura T, Tanaka H, Miyamatsu N, et al. NIPPON DATA80 Research Group The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis. 2007 ; 190 (1). 216-223
14. Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006 ; 368 (9542). 1155-1163
15. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001 ; 285 (19). 2486-2497
16. Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the return on expenditure achieved for lipid therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008 ; 24 (7). 1951-1963
17. Nitiyanant W, Sritara P, Deerochanawong C, Ngarmukos P, Koanantakul B. Lipid treatment assessment project II in Thailand (LTAP-II Thailand). J Med Assoc Thai. 2008 ; 91 (6). 836-845
18. Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs. 2006 ; 6 (6). 383-391
19. Lee KK, Lee VW, Chan WK, et al. Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: results of the Hong Kong hospital audit study. Value Health. 2008 ; 11 (suppl 1). S91 - S98
20. Wu YF. The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007 ; 35 (5). 420-427
21. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education program adult treatment panel III guidelines. Circulation. 2004 ; 110 (2). 227-239
22. Nichols GA, Ambegaonkar BM, Sazonov V, Brown JB. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol. 2009 ; 104 (12). 1689-1694
23. Phatak H, Wentworth C, Sazonov V, Burke T. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis. 2009 ; 202 (1). 225-233
24. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011 ; 97 (5). 350-356
25. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 ; 362 (17). 1563-1574
26. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J. 2011 ; 161 (3). 471-477 e472
27. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007 ; 18 (4). 415-420
28. Miyares MA. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Ann Pharmacother. 2011 ; 45 (1). 84-94
29. Katcher HI, Hill AM, Lanford JL, Yoo JS, Kris-Etherton PM. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am. 2009 ; 38 (1). 45-78